Age-Related Macular Degeneration Happenings at the Foundation
At the Retina Foundation, our Laboratory Directors often partner with various pharmaceutical and biotechnology companies to conduct clinical trials and research.
In our Clinical Center of Innovation for Age-Related Macular Degeneration (AMD), led by Karl Csaky, M.D., Ph.D., Chief Executive and Medical Officer of the Foundation, we currently have 15 studies for AMD and geographic atrophy (GA), along with 2 studies focusing on Stargardt’s disease. The goal of these studies is to focus on treatment of AMD, GA, and Stargardt’s disease, as well as gain a better understanding of these AMD-related conditions.
For an in-depth vision evaluation, genetic testing and counseling, or a personalized treatment plan in our Clinical Center of Innovation for Age-Related Macular Degeneration, visit www.retinafoundation.org/amdpatient to learn more and request an appointment!
The AMD studies that the Foundation is currently enrolling for include:
Non-Exudative Age-Related Macular Degeneration Imaged with Swept Source Optical Coherence Tomography, sponsored by Boston Image Reading Center; Clinicaltrials.gov Identifier NCT#: 03688243
A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability and Efficacy of Intravitreal Injections in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration, sponsored by Genetech, Inc.; Clinicaltrials.gov Identifier NCT#: 03972709
A Study of Disease Progression in Genetically Defined Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration, sponsored by Gyroscope Therapeutics; Clinicaltrials.gov Identifier NCT#: 03894020
Age-Related Macular Degeneration Ryan Initiative Study, sponsored by the National Eye Institute (NEI); Clinicaltrials.gov Identifier NCT#: 03092492
A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration, sponsored by Ionis Pharmaceuticals, Inc.; Clinicaltrials.gov Identifier NCT#: 03815825
To learn more about these trials, as well as sign up, please visit www.retinafoundation.org/amd. To view these studies on www.clinicaltrials.gov, search by “Retina Foundation.” Further, you can also select “Recruiting and not yet recruiting.”
We’re excited to share our current and ongoing studies and will keep you updated on future research happenings at the Foundation!
Please consider donating to the Retina Foundation to support our mission to prevent vision loss and restore sight through innovative research and treatment.
Related ArticlesThe Edward C. Fogg, III and Lisbeth A. Fogg Charitable Trust grants Retina Foundation $133,000 for Genetic Eye Disease Retina Foundation Completes $3.7M Capital Campaign Gene Causing Blindness Found in Texas Hispanic Families Retina Foundation 20/20 Video Research Updates Developing a Treatment for Age-Related Macular Degeneration – Video Update